Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Carleton University

$25,000.00

Surface Plasmon Resonance -Tilted Fibre Bragg Grating (SPR-TFBG) fibre optic biosensor to detect metastasized cancer cells in cancer patients

EF 2013-14

Résumé
Spartan Bioscience Inc. is a leader in point-of-care DNA testing. They were the first to complete sample-to-result DNA testing system in medicine and have the Spartan RX and DX-12 DNA testing instruments currently on the market. Spartan is now currently interested in developing new technologies for the detection of metastasized tumor cells in cancer patients. The detection of cancer metastasis is an ongoing problem when utilizing the current technologies. Recently, a group at Carleton have developed a fibre optic biosensor that relies on Surface Plasmon Resonance (SPR) to detect the attachment of biomolecules, and even whole cells, onto the fibre's surface. This SPR device relies on a Tilted Fibre Bragg Grating (TFBG), imprinted into the fibre's core, to reflect light from the surface of the fibre and back down the fibre to a detector. Attachment events at the surface of the fibre are detected as changes in the SPR signal, which can include attachment/deattachment of cells to the fibre. The surface of the fibre can be functionalized to make it more cancer-specific with the attachment of DNA aptamers that recognize, and bind to, specific proteins uniquely expressed at the surface of the cancer cell. Spartan Bioscience has encountered challenges in developing such technology in that it does not have the in-house capabilities to a) manufacture such SPR-TFBG fibres, b) functionalize the surface of such fibres with DNA aptamers, or c) test them in cell culture for cancer versus non-cancer binding of cells. The company also does not have the analytical tools or the research personnel to solve this problem. The NSERC ENGAGE grant will be utilized as proof-of- principle testing of the fibre optic biosensor to a) attach DNA aptamers against mucin-1, a breast cancer marker, to the fibre itself and b) test for the attachment of a breast cancer cell (MCF7) versus non-cancer cell (MCF10). This endeavor will represent a new collaboration between Spartan Bioscience and our lab and will involve a multidisciplinary team of researchers (engineers, chemists and biochemists) to solve the problem. The duration of this project is expected to be 6 months and will serve as a basis for applications for a CIHR/NSERC CHRP grant.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
453689-2013
Name nom
Willmore, William
Department département
Biochemistry, Institute of
Organization id
23
Institution établissement
Carleton University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Surface Plasmon Resonance -Tilted Fibre Bragg Grating (SPR-TFBG) fibre optic biosensor to detect metastasized cancer cells in cancer patients
Keyword
NSERC
Application summary
Spartan Bioscience Inc. is a leader in point-of-care DNA testing. They were the first to complete sample-to-result DNA testing system in medicine and have the Spartan RX and DX-12 DNA testing instruments currently on the market. Spartan is now currently interested in developing new technologies for the detection of metastasized tumor cells in cancer patients. The detection of cancer metastasis is an ongoing problem when utilizing the current technologies. Recently, a group at Carleton have developed a fibre optic biosensor that relies on Surface Plasmon Resonance (SPR) to detect the attachment of biomolecules, and even whole cells, onto the fibre's surface. This SPR device relies on a Tilted Fibre Bragg Grating (TFBG), imprinted into the fibre's core, to reflect light from the surface of the fibre and back down the fibre to a detector. Attachment events at the surface of the fibre are detected as changes in the SPR signal, which can include attachment/deattachment of cells to the fibre. The surface of the fibre can be functionalized to make it more cancer-specific with the attachment of DNA aptamers that recognize, and bind to, specific proteins uniquely expressed at the surface of the cancer cell. Spartan Bioscience has encountered challenges in developing such technology in that it does not have the in-house capabilities to a) manufacture such SPR-TFBG fibres, b) functionalize the surface of such fibres with DNA aptamers, or c) test them in cell culture for cancer versus non-cancer binding of cells. The company also does not have the analytical tools or the research personnel to solve this problem. The NSERC ENGAGE grant will be utilized as proof-of- principle testing of the fibre optic biosensor to a) attach DNA aptamers against mucin-1, a breast cancer marker, to the fibre itself and b) test for the attachment of a breast cancer cell (MCF7) versus non-cancer cell (MCF10). This endeavor will represent a new collaboration between Spartan Bioscience and our lab and will involve a multidisciplinary team of researchers (engineers, chemists and biochemists) to solve the problem. The duration of this project is expected to be 6 months and will serve as a basis for applications for a CIHR/NSERC CHRP grant.